AU2020100093A4 - Isonicotinic acid derivative and preparation method and application thereof technical field - Google Patents

Isonicotinic acid derivative and preparation method and application thereof technical field Download PDF

Info

Publication number
AU2020100093A4
AU2020100093A4 AU2020100093A AU2020100093A AU2020100093A4 AU 2020100093 A4 AU2020100093 A4 AU 2020100093A4 AU 2020100093 A AU2020100093 A AU 2020100093A AU 2020100093 A AU2020100093 A AU 2020100093A AU 2020100093 A4 AU2020100093 A4 AU 2020100093A4
Authority
AU
Australia
Prior art keywords
isoxazole
alkyl
cancer
page
jan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020100093A
Inventor
Canzhong LU
Jianping Yong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiamen Institute of Rare Earth Materials
Original Assignee
Xiamen Institute of Rare Earth Materials
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiamen Institute of Rare Earth Materials filed Critical Xiamen Institute of Rare Earth Materials
Application granted granted Critical
Publication of AU2020100093A4 publication Critical patent/AU2020100093A4/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

An embodiment of the present disclosure mainly relates to an isonicotinic acid derivative, a stereoisomer, a racemate, a tautomer, or a pharmaceutically acceptable salt thereof represented by the formula (I), a preparation method thereof, and its use in preparation of anticancer drugs. In formula (I), Z is selected from 0, S, and NR3, wherein R3 is hydrogen or CI-C6 alkyl; R1 is selected from C1 -C 6 alkyl, C1 -C 6 alkoxy, and halogenated C1 -C 6 alkyl, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclyloxy, halogen; R2 is selected from halogen, cyano, nitro, C1 ~ C6 alkyl, C1 ~ C6 alkoxy or halogenated CI-C 6 alkyl; m is an integer from 0-4; n is an integer from 0-5; provided that when Z is selected from NR3 , m is 0, and n is 1, R2 is not halogen. m(R1) (R2 )n (I)

Description

ISONICOTINIC ACID DERIVATIVE AND PREPARATION METHOD AND APPLICATION THEREOF TECHNICAL FIELD
Embodiments of the present disclosure belong to the field of medicinal chemistry and relate to a class of isonicotinic acid derivatives with novel structures, in particular to isonicotinate derivatives and isonicotinamide derivatives containing isoxazole heterocycles, and preparation methods and uses thereof.
BACKGROUND
Cancer is a large class of diseases characterized by abnormal cell proliferation and metastasis. It is the second leading cause of death in humans, second only to cardiovascular and cerebrovascular diseases. Cancer can occur in various organs and tissues at any age. According to statistics of the World Health Organization, in 2018, there were approximately 18.1 million new cancer cases and 9.6 million cancer deaths worldwide. There were new cancer cases in Asia (of 8751,000 people) with 48.4% incidence, and cancer death cases (5477,000 people) with 57.3% mortality; There were new cancer cases in Europe (4230000 people) with 23.4% incidence, and cancer death cases (1943,000) with 20.3% mortality; There were new cancer cases in America (3792,000) with 21.0% incidence, and cancer death cases (1371,000) with 14.4% mortality; There were new cancer cases in Africa (1055,000 people) with 5.8% incidence, and cancer death cases (693,000 people) with 7.3% mortality; There were new cancer cases in Oceania (252,000 people) with 1.4% incidence, and cancer death cases (70,000) with 0.7% mortality. From the statistics above, it could be seen that Asia had the highest incidence of cancer and the highest mortality rate. Among them, compared with other countries, incidence and mortality in China ranked first in the world. Of the 18.1 million new cancer patients, China accounted for 3.804 million, and of the 9.6 million cancer deaths, China accounted for 2.296 million. It implied that for every 100 new cancer patients in the world, 21 of which were Chinese. In other words, it meant that an average of 7 people are diagnosed with cancer every minute in our country, and nearly 5 people died from cancers every minute.
The main types of cancer that cause death are: lung cancer, breast cancer, colorectal cancer, prostate cancer, and gastric cancer. Among them, the incidence of lung cancer is 11.6% and the mortality of it is 18.4%; the incidence of breast cancer is 11.6% and the
Page 1
2020100093 17 Jan 2020 mortality of it is 6.6%; the incidence of colorectal cancer is 10.2% and the mortality of it is 9.2%; the incidence of gastric cancer is 5.7% and the mortality rate of it is 8.2%. However, in China, the incidence of lung cancer is the highest. For males, gastric cancer, liver cancer, colorectal cancer, and esophageal cancer are high-incidence cancers; for females, breast cancer, colorectal cancer, thyroid cancer, and gastric cancer are also high-incidence cancers.
However, most cancers are discovered in the middle to advanced stages, and the overall effect of treatment is poor. Cancer has posed a huge threat to human survival.
Methods related to cancer treatment include: surgery, radiation therapy and chemotherapy, etc.. Surgical treatment sometimes fails to eradicate cancer cells, which makes them spread and recur. In addition, surgical treatment may lead to serious irrecoverable consequences. For example, cervical and bladder cancer surgeries may cause infertility and sexual dysfunction, etc.; radiation treatment of cancer will damage normal cells; therefore, drug treatment is a better choice. However, the continuous emergence of multidrug resistance has made cancer treatment difficult. In addition, at present, the anticancer drugs used in clinical practice still fail to reach a satisfactory degree of specificity. When patients undergo chemotherapy, normal cells in the body are often killed together, which seriously affects normal physiological functions and is accompanied by many side effects. Therefore, specific anticancer drugs with high activities and low side effects must be developed to meet clinical needs.
Pyridine derivatives have a broad spectrum of biological activities, such as bacteriostatic, anti-inflammatory, activities against cardiovascular diseases, blood lipid lowering, anti-platelet aggregation, activity as plant growth regulator and the like. The patent document CN1953748A also reports that nicotinic acid derivatives have activities to prevent and treat cancers; the patent document CN101210012A reports that nicotinic acid derivatives have activities such as reducing glucose, lowering blood lipids, lowering blood pressure, as well as anticancer, antibacterial, and antiviral activities. In recent years, our group has been mainly engaged in the design and synthesis of compound libraries of small molecule anticancer drugs. Good results have been obtained in previous research work (CN103360382A, CN103664991A, CN103601762A). However, the activity of the above compounds needs to be further improved.
SUMMARY
Page 2
2020100093 17 Jan 2020
The purpose of an embodiment of the present disclosure is to provide an isonicotinic acid derivative represented by the formula (I). After activity studies, it has been shown that the isonicotinic acid derivative have strong inhibitory activity against human lung cancer cell line A549, colorectal cancer cell line HCT-116 and breast cancer cell line MCF-7. Therefore, it can be used as candidate compounds or lead compounds of anticancer drugs.
An embodiment of the present disclosure is achieved through the following technical solutions:
an isonicotinic acid derivative represented by formula (I), a stereoisomer, a racemate, a tautomer, or a pharmaceutically acceptable salt thereof,
Figure AU2020100093A4_D0001
(I) wherein,
Z is selected from the group consisting of O, S, and NR3, wherein R3 is hydrogen or Ci~C6~ alkyl;
Ri is selected from the group consisting of Ci~C6 alkyl, Ci~C6 alkoxy, halogenated C1-C6 alkyl, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclyloxy and halogen;
R2 is selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 alkoxy, and halogenated C1-C6 alkyl;
m is an integer from 0 to 4;
n is an integer from 0 to 5;
provided that when Z is NR3, m is 0 and n is 1, R2 is not a halogen.
According to a preferred technical solution of embodiments of the present disclosure, wherein in formula (I):
Z is O or NH;
Ri is selected from the group consisting of fluorine, chlorine, bromine, Ci~C4 alkyl,
Cj~C4 alkoxy, halogenated Ci~C4 alkyl, and phenoxy;
R2 is selected from the group consisting of fluorine, chlorine, bromine, nitro, Ci~C4
Page 3
2020100093 17 Jan 2020 alkyl, Ci~C4 alkoxy, and halogenated Ci~C4 alkyl;
m is an integer of 0, 1, 2; when m is greater than 1, Ri may be the same or different groups;
n is an integer of 0, 1, 2, 3; when n is greater than 1, R2 may be the same or different groups;
provided that when Z is NR3, m is 0 and n is 1, R2 is not fluorine, chlorine, or bromine.
Preferably, wherein in the formula (I), Z is O;
Ri is selected from 2- and / or 6-position substituents on 3-pyridyl, and the substituents are selected from the group consisting of fluorine, chlorine, bromine, Ci~C4 alkyl, and Ci~C4 alkoxy;
R2 is selected from 2- and / or 4- and / or 6-position substituents on 1-phenyl, and the substituents are selected from the group consisting of fluorine, chlorine, bromine, nitro, Cj~C4 alkyl, Ci~C4 alkoxy and halogenated Ci ~ C4 alkyl.
According to embodiments of the present disclosure, the isonicotinic acid derivative represented by the formula (I) is selected from any one of the following compounds:
Figure AU2020100093A4_D0002
Page 4
2020100093 17 Jan 2020
Figure AU2020100093A4_D0003
Figure AU2020100093A4_D0004
Figure AU2020100093A4_D0005
Figure AU2020100093A4_D0006
Figure AU2020100093A4_D0007
Page 5
2020100093 17 Jan 2020
Figure AU2020100093A4_D0008
Figure AU2020100093A4_D0009
Figure AU2020100093A4_D0010
Page 6
2020100093 17 Jan 2020
Figure AU2020100093A4_D0011
Page 7
2020100093 17 Jan 2020
Figure AU2020100093A4_D0012
Figure AU2020100093A4_D0013
Figure AU2020100093A4_D0014
Figure AU2020100093A4_D0015
Figure AU2020100093A4_D0016
Figure AU2020100093A4_D0017
Figure AU2020100093A4_D0018
Figure AU2020100093A4_D0019
Page 8
Figure AU2020100093A4_D0020
Figure AU2020100093A4_D0021
Figure AU2020100093A4_D0022
The isonicotinic acid derivative represented by formula (I) can be selected to form a pharmaceutically acceptable salt with a pharmaceutically acceptable acid, respectively. Wherein the term pharmaceutically acceptable salt includes, but is not limited to, salts formed with inorganic acids, for example, hydrochloride, phosphate, diphosphate, hydrobromide, sulfate, sulfinate, nitrate, etc.; and salts formed with organic acids such as lactic acid, oxalic acid, malate, maleate, fumarate, tartrate, succinate, citrate, lactate, sulfonate , P-toluenesulfonate, 2-isethionate, benzoate, salicylate, stearate, trifluoroacetic acid, amino acid, alkanoate such as acetate, salts formed with H00C-(CH2)s-C00H, wherein s is 0-4, and the like. Similarly, pharmaceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium, and ammonium.
An embodiment of the present disclosure also provides a pharmaceutical composition
Page 9
2020100093 17 Jan 2020 comprising a therapeutically effective amount of at least one selected from the compound of formula (I), the stereoisomer, racemate, tautomer, and pharmaceutically acceptable salt thereof.
According to embodiments of the present disclosure, the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient. The excipient may be inert, non-toxic excipients, carriers or diluents, for example, the excipient is selected from one, two or more of the following: disintegrants, glidants, lubricants, fillers, binders, colorants, effervescents, flavoring agents, preservatives, coating materials, etc.
Embodiments of the present disclosure also provide a pharmaceutical preparation comprising at least one selected from the compound represented by formula (I) of embodiments of the present disclosure, the stereoisomer, racemate, tautomer, and pharmaceutically acceptable salt thereof.
According to embodiments of the present disclosure, the preparation is preferably a solid oral preparation, a liquid oral preparation or an injection.
According to embodiments of the present disclosure, the preparation is selected from the group consisting of tablets (dispersed tablets, enteric tablets, chewable tablets, orally disintegrating tablets), capsules, granules, oral solutions, solution-type injections, lyophilized powder injections, large infusions and small infusions.
Embodiments of the present disclosure also provide a use of at least one selected from the isonicotinic acid derivative represented by formula (I), the stereoisomer, racemate, tautomer, and pharmaceutically acceptable salt thereof in preparation of anticancer drugs.
According to embodiments of the present disclosure, the cancer is associated with excessive expression and / or activity of EGFR.
Preferably, the cancer is selected from the group consisting of intestinal cancer, bladder cancer, ovarian cancer, breast cancer, gastric cancer, esophageal cancer, lung cancer, head and neck cancer, colon cancer, pharyngeal cancer, and pancreatic cancer.
Further preferably, the cancer is non-small cell lung cancer (NSCLC), bowel cancer, bowel cancer or breast cancer.
An embodiment of the present disclosure also provides a method for preparing the isonicotinic acid derivative represented by formula (I), including the following steps:
Page 10
2020100093 17 Jan 2020
Figure AU2020100093A4_D0023
(III) (II)
Figure AU2020100093A4_D0024
(I) reacting a compound represented by formula (III) with a compound represented by formula (II) to obtain the compound of formula (I);
wherein, each Ri, R2, Z, m, n independently has the definition described above; X is a leaving group;
preferably, X is selected from hydroxyl or Cl;
If protection is required, any functional group in formula (II) and formula (III) may be protected, and thereafter, if necessary, in any order:
(1) removing any protective agent, and (2) forming a pharmaceutically acceptable salt of the compound of formula (I).
According to the preparation method of embodiments of the present disclosure, the reaction is preferably performed under the action of a condensing agent selected from dicyclohexylcarbodiimide (DCC), carbonyldiimidazole (CDI) or 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI · HC1).
According to embodiments of the present disclosure, an activator is preferably further used with the condensing agent, and the activator is selected from at least one of 1hydroxybenzotriazole (HOBT), N, N-diisopropylethylamine and 4-dimethylaminopyridine (DMAP).
According to the preparation method of embodiments of the present disclosure, the temperature of the reaction is -20 °C to reflux temperature of a solvent used, preferably 0 °C to 30 °C.
According to the preparation method of embodiments of the present disclosure, the reaction is performed in an organic solvent, and the organic solvent is at least one of benzene, toluene, xylene, dichloromethane, chloroform, acetonitrile, dioxane, tetrahydrofuran, and DMF. Tetrahydrofuran is preferred.
According to the preparation method of embodiments of the present disclosure, the
Page 11
2020100093 17 Jan 2020 reaction is performed in the presence of a basic catalyst, which is an organic base or an inorganic base, and the organic base is preferably triethylamine, tripropylamine, DMAP, potassium tert-butoxide, etc. ; The inorganic base is preferably potassium carbonate, sodium hydride, or sodium carbonate.
Definition and description of terms
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of skilled person in the art to which the subject matter of the claims belongs.
When a numerical range described in the specification and claims of this application is defined as an integer, it should be understood that the two endpoints of the range and each integer in the range are recorded. For example, “integer from 0 to 4” should be understood as each integer of 0, 1, 2, 3, and 4 is recorded. More means three or more.
Halogen refers to F, Cl, Br and I.
Cj~C6 alkyl group refers to an alkyl group with a straight or branched chain having Ιό carbon atoms. Ci-Ce alkyl group is, for example, methyl, ethyl, propyl, isopropyl, butyl, iso Butyl, tert-butyl, sec-butyl, pentyl, or neopentyl.
Cj~C6 alkoxy group refers to an -O-Ci~C6 alkyl group, wherein the Ci~C6 alkyl group is as defined above.
Halogenated Ci~C6 alkyl group refers to a group in which any one, two, or more hydrogens of the carbon chain of the Ci~C6 alkyl group is substituted with halogen.
Aryl group refers to a monocyclic or polycyclic aromatic group having 6-20 (preferably 6-14) carbon atoms, and representative aryl groups include: phenyl, naphthyl, anthracenyl, fluorenyl and the like.
Aryloxy group means -O-aryl, wherein aryl is as defined above.
Heteroaryl group refers to a monocyclic or polycyclic aromatic group having 6-20 carbon atoms and 1-4 heteroatoms selected from N, S, and O heteroatoms. Representative heteroaryl groups include thienyl, furyl, pyrrolyl, pyridyl, pyrimidinyl, imidazolyl, thiazolyl, indolyl, azanaphthyl, azaanthryl, azafluorenyl and the like.
Heteroaryloxy refers to -O-heteroaryl, wherein heteroaryl is as defined above.
Heterocyclic group refers to a monocyclic or polycyclic non-aromatic group having 3-20
Page 12
2020100093 17 Jan 2020 carbon atoms and 1-4 heteroatoms selected from N, S, and O heteroatoms. In particular, the heterocyclic group may include, but is not limited to, a 4-membered ring such as azetidinyl and oxetanyl; a 5-membered ring such as tetrahydro furanyl, dioxolyl, and pyrrolidinyl, imidazolidinyl, pyrazolidinyl, pyrrolinyl; or a 6-membered ring, such as tetrahydropyranyl, piperidinyl, morpholinyl, dithioalkyl, thiomorpholinyl, piperazinyl or trithiaalkyl; or a 7membered ring, such as diazacycloheptyl. Optionally, the heterocyclyl may be benzofused. The heterocyclic group may be bicyclic, such as but not limited to a 5,5-membered ring, such as a hexahydrocyclopenta [c] pyrrole-2 (1H) -yl ring, or a 5 or 6-membered bicyclic ring, such as hexahydropyrrole [ 1,2-a] pyrazine-2 (1H) -yl ring.
Heterocyclyloxy refers to -O-heterocyclyl, wherein heterocyclyl is as defined above.
The term effective amount refers to an amount of at least one compound and / or at least one pharmaceutically acceptable salt that is effective to treat a disease or discomfort in an individual. In the case of cancer, the effective amount can reduce the number of cancer or tumor cells; reduce the size of the tumor; inhibit or prevent the invasion of tumor cells into surrounding organs, for example, inhibit tumors spread into soft tissue or bone; inhibit or prevent the metastasis of the tumor; inhibit or prevent tumor growth; reduce one or more cancer-related symptoms to a certain extent; reduce morbidity and mortality; improve quality of life; or a combination of the above effects. The effective amount can be an amount that reduces disease symptoms by inhibiting EGFR activity. For cancer treatment, the effects of in vivo experiments can be measured by assessing, for example, survival time, time to disease progression (TDP), response rates (RR), duration of response, and / or quality of life.
Those skilled in the art have recognized that the effective amount may vary depending on the route of administration, the dosage of the excipient, and the combination with other drugs.
The term effective amount may also refer to a dose that is effective for inhibiting overexpression of EGFR and / or being overactive for at least one of the compound and / or at least one pharmaceutically acceptable salt thereof.
Beneficial effects
The compound of the disclosure has antitumor and anticancer activities, in particular has
Page 13
2020100093 17 Jan 2020 strong inhibitory activities on human lung cancer cell line A549, colorectal cancer cell line HCT116 and breast cancer cell line MCF-7 with high expression of EGFR. The compound YP-1 shows strong activity on three tumor cell lines (A549, HCT116 and MCF-7), among which, compound YP-1 shows strong inhibitory activity on A549 and HCT116 cell lines in vitro, with IC50 values of 4.73 x IO'6 and 3.60 x IO'6 pm, respectively, while the IC50 values of gefitinib on A549 and HCT116 are 21.6 and 17.9 pm, respectively; compound YP-28 on three tumor cell lines (A549, HCT116 and MCF-7) shows strong inhibitory activity, which is similar to that of gefitinib in A549 cell line.
Therefore, the compound of embodiments of the present disclosure has broadspectrum anticancer and antitumor activities and can be used as a candidate drug or a leading compound for treating tumors and cancers.
DETAILED DESCRIPTION
Embodiments of the present disclosure will be further described with reference to the following embodiments. It should be noted that the following embodiments cannot be used as a limitation on the protection scope of embodiments of the present disclosure, and any improvement based on embodiments of the present disclosure do not violate the spirit of embodiments of the present disclosure.
Among them, the synthesis processes of intermediates and target compounds are described by the representatives in the examples, and the synthesis processes of the remaining intermediates and target compounds are the same as the representative compounds.
Instruments and reagents:
AVANCE III nuclear magnetic resonance instrument (400 MHz, DMSO-de, TMS as the internal standard), ion trap liquid mass spectrometer (DECAX-30000 LCQ Deca XP), adjustable wavelength microplate reader (Molecular Devices SPECTRAMAX190). Tunable wavelength microplate reader (Molecular Devices SPECTRAMAX190). The chemical reagents are all commercially available analytical or chemical reagents. RPMI1640 is purchased from Gibco, and thiazole blue [3- (4, 5-dimethylthiazol-2-yl) -2,5diphenyltetrazolium bromide, MTT] is purchased from Sigma. The other reagents are all commercially available and of analytical grades which are not treated before being used
Page 14
2020100093 17 Jan 2020 unless special instruction is given. Tetrahydro furan is treated with dry molecular sieve before use.
Example 1 Synthesis of intermediate 3-substituted phenyl-5-hydroxymethyl-isoxazole (II1) or intermediate 3-substituted phenyl-5-aminomethyl-isoxazole (Π-2):
Using substituted benzaldehyde as a raw material, it is prepared by synthesis of oxime, 1,3-dipolar cycloaddition reaction, methanesulfonyl esterification reaction, azidation, reduction reaction (R2 and n are as defined above), referring to the following process in details:
/ d x if^CHO NH3OH .HCI, Na2CO3 /^_C=NOH n(R2) J ------------------------► n( R2Jqr J H
25°C
NCS / Et3N λ XO MsCI / Et3N * n( R2T-N- I \___/ * °C-reflux Xx0H 0 °C - r. t.
(H-1)
Figure AU2020100093A4_D0025
Figure AU2020100093A4_D0026
(HI-2)
The detailed preparation processes of intermediate 3-substituted phenyl-5 -hydroxymethyl-isoxazole (II-1) or intermediate 3-substituted phenyl-5-aminomethylisoxazole (II-2) are referring to the three applications of the applicant's earlier applications with publication numbers CN103360382A, CN103664991A, and CN103601762A, of which the entire contents are incorporated herein by reference.
Example 2 Synthesis of the isonicotinic acid derivative represented by formula (I), which is illustrated by the reaction between isonicotinic acid and 3-phenyl-5-hydroxymethylisoxazole:
Synthesis of [(3-phenyl-isoxazol-5-yl) -methyl] -pyridine-3-carboxylate (YP-77)
Page 15
2020100093 17 Jan 2020
Figure AU2020100093A4_D0027
0.123 g (1 mmol) niacin and 0.206 g (1 mmol) DCC were added to a 50 mL roundbottomed flask, added with 10 mL dry THF, and stirred in an ice bath for 30 minutes. Then, a solution of 0.175 g (1 mmol) 5- hydroxymethyl-3-phenyl-isoxazole and 0.122 g (1 mmol) DMAP in 10 mL THF were slowly added dropwise to the reaction system, and the reaction solution was allowed to naturally rise to room temperature after stirring for 30 minutes in an ice bath. After the completion of the TLC detection reaction, the reaction solution is concentrated in vacuo and the residue is directly separated by column (V (petroleum ether): V (ethyl acetate) = 5:1-2:1) to obtain the target compound [(3-phenyl- isoxazol5-yl) -methyl] -pyridine-3-formate (YP-77).
The compounds in the following table are also synthesized according to the method of example 2. The characterization data of compound Y-77 and the other compounds are:
Table 1- mass spectrometry data of compounds
No. MS (m/e, 100%) NO. MS (m/e, 100%)
YP-1 344 ([M]+, 15) YP-2 376 ([M+18]+, 10)
YP-3 372 ([M]+, 80) YP-4 401 ([M+l]+, 80)
YP-5 386 ([M]+, 45) YP-6 374 ([M]+, 15)
YP-7 374 ([M]+, 60) YP-8 374 ([M]+, 45)
YP-9 412 ([M]+, 75) YP-10 412 ([M]+, 65)
YP-11 362 ([M]+, 60) YP-12 362 ([M]+, 75)
YP-13 381 ([M+2]+, 10) YP-14 379 ([M]+, 10)
YP-15 413 ([M]+, 75) YP-16 424 ([M+l]+, 48)
YP-17 423 ([M]+, 65) YP-18 423 ([M]+, 55)
YP-19 389 ([M]+, 15) YP-20 328 ([M]+, 60)
YP-21 342 ([M]+, 85) YP-22 356 ([M]+, 75)
YP-23 384 ([M]+, 75) YP-24 370 ([M]+, 50)
Page 16
2020100093 17 Jan 2020
YP-25 358 ([M]+, 15) YP-26 358 ([M]+, 75)
YP-27 358 ([M]+, 65) YP-28 396 ([M]+, 15)
YP-29 396 ([M]+, 75) YP-30 346 ([M]+, 70)
YP-31 346 ([M]+, 35) YP-32 363 ([M]+, 100)
YP-33 365 ([M+2]+, 20) YP-34 397 ([M]+, 55)
YP-35 407 ([M]+, 100) YP-36 407 ([M]+, 85)
YP-37 408 ([M+l]+, 85) YP-38 373 ([M]+, 100)
YP-39 344 ([M+l]+, 100) YP-40 358 ([M+l]+, 80)
YP-41 372 ([M+l]+, 80) YP-42 400 ([M+l]+, 90)
YP-43 386 ([M+l]+, 60) YP-44 374 ([M+l]+, 85)
YP-45 374 ([M+l]+, 65) YP-46 374 ([M+l]+, 65)
YP-47 412 ([M+l]+, 55) YP-48 412 ([M+l]+, 65)
YP-49 362 ([M+l]+, 55) YP-50 362 ([M+l]+, 85)
YP-51 379 ([M+l]+, 55) YP-52 379 ([M+l]+, 55)
YP-53 413 ([M+l]+, 85) YP-54 403 ([M+l]+, 85)
YP-55 403 ([M+l]+, 25) YP-56 403 ([M+l]+, 100)
YP-57 389 ([M+l]+, 95) YP-58 328 ([M+l]+, 100)
YP-59 342 ([M+l]+, 100) YP-60 356 ([M+l]+, 100)
YP-61 384 ([M+l]+, 100) YP-62 370 ([M+l]+, 80)
YP-63 358 ([M+l]+, 70) YP-64 358 ([M+l]+, 40)
YP-65 358 ([M+l]+, 100) YP-66 396 ([M+l]+, 80)
YP-67 396 ([M+l]+, 60) YP-68 346 ([M+l]+, 100)
YP-69 346 ([M+l]+, 100) YP-70 363 ([M+l]+, 100)
YP-71 363 ([M+l]+, 100) YP-72 397 ([M+l]+, 80)
YP-73 407 ([M+l]+, 100) YP-74 407 ([M+l]+, 50)
YP-75 407 ([M+l]+, 60) YP-76 373 ([M+l]+, 100)
YP-77 280 ([M]+, 100) YP-78 294 ([M]+, 100)
YP-79 208 ([M]+, 90) YP-80 236 ([M]+, 90)
YP-81 322 ([M]+, 100) YP-82 310 ([M]+, 100)
Page 17
2020100093 17 Jan 2020
YP-83 310 ([M]+, 80) YP-84 310 ([M]+, 60)
YP-85 348 ([M]+, 80) YP-86 348 ([M]+, 80)
YP-87 298 ([M]+, 100) YP-88 298 ([M]+, 80)
YP-89 314 ([M]+, 100) YP-90 314 ([M]+, 100)
YP-91 349 ([M]+, 90) YP-92 359 ([M]+, 100)
YP-93 359 ([M]+, 90) YP-94 359 ([M]+, 60)
YP-95 325 ([M]+, 100) YP-98 307 ([M+l]+, 80)
YP-97 294 ([M+l]+, 100) YP-100 321 ([M+l]+, 90)
YP-99 336 ([M+l]+, 90) YP-102 310 ([M+l]+, 90)
YP-101 310 ([M+l]+, 90) YP-104 348 ([M+l]+, 90)
YP-103 310 ([M+l]+, 90) YP-106 298 ([M+l]+, 100)
YP-105 348 ([M+l]+, 90) YP-108 314 ([M+l]+, 100)
YP-107 298 ([M+l]+, 100) YP-110 349 ([M+l]+, 100)
YP-109 314 ([M+l]+, 100) YP-112 359 ([M+l]+, 80)
YP-111 359 ([M+l]+, 100) YP-114 325 ([M+l]+, 100)
YP-113 359 ([M+l]+, 90)
Table 2-1 H NMR data of representative compounds in Table 1
NO. *H NMR (400 MHz, DMSO-</6)
YP-1 3.92 (s, 3H, OCH3), 5.59 (s, 2H, isoxazole-CH2), 7.28 (s, 1H, isoxazole), 7.30 (s, 1H), 7.50-7.53 (m, 4H), 7.89-7.91 (m, 2H).
YP-2 2.37 (s, 3H, CH3), 3.92 (s, 3H, OCH3), 5.58 (s, 2H, isoxazole-CH2), 7.24 (s, 1H, isoxazole), 7.29 (d, J= 1.2 Hz, 1H), 7.34 (d, J= 8.0 Hz, 2H), 7.50 (d, J = 1.2 Hz, 1H), 7.80 (d, J= 8.0 Hz, 2H).
YP-3 1.29 (t, 3H, CH3, J= 7.6 Hz), 2.72 (q, 2H, CH2, J= 7.6 Hz), 3.92 (s, 3H, OCH3), 5.58 (s, 2H, isoxazole-CH2), 7.24 (s, 1H, isoxazole), 7.29 (d, J= 1.2 Hz, 1H), 7.34 (d, J=8.0Hz, 2H), 7.50 (d, J= 1.2 Hz, 1H), 7.80 (d,J=8.0 Hz, 2H).
YP-4 1.35 (s, 9H, 3CH3), 3.92 (s, 3H, OCH3), 5.58 (s, 2H, isoxazole-CH2), 7.24 (s,
Page 18
2020100093 17 Jan 2020
1H, isoxazole), 7.29 (d, J= 1.2 Hz, 1H), 7.34 (d, J= 8.0 Hz, 2H), 7.50 (d, J = 1.2 Hz, 1H), 7.80 (d, J= 8.0 Hz, 2H).
YP-5 2.15 (s, 6H, 2CH3), 2.31 (s, 3H, CH3), 3.92 (s, 3H, OCH3), 5.58 (s, 2H, isoxazole-CH2), 7.24 (s, 1H, isoxazole), 7.29 (d, J= 1.2 Hz, 1H), 7.34 (d, J = 8.0 Hz, 2H), 7.50 (d, J= 1.2 Hz, 1H), 7.80 (d, J= 8.0 Hz, 2H).
YP-6 3.82 (s, 3H, OCH3), 3.92 (s, 3H, OCH3), 5.56 (s, 2H, isoxazole-CH2), 7.08 (d, J= 8.8 Hz, 2H), 7.21(s,lH, isoxazole), 7.29 (d, J= 1.2 Hz, 1H), 7.50 (d, J = 0.8 Hz, 1H), 7.84 (d, J= 8.8 Hz, 2H).
YP-7 3.82 (s, 3H, OCH3), 3.92 (s, 3H, OCH3), 5.56 (s, 2H, isoxazole-CH2), 7.017.08 (m, 2H), 7.42-7.46 (m, 1H), 7.21 (s,lH, isoxazole), 7.29 (d, J= 1.2 Hz, 1H), 7.50 (d, J=0.8 Hz, 1H), 8.17-8.20 (m, 1H).
YP-8 3.82 (s, 3H, OCH3), 3.92 (s, 3H, OCH3), 5.56 (s, 2H, isoxazole-CH2), 7.21 (s, 1H, isoxazole), 7.29 (d, J= 1.2 Hz, 1H), 7.38-7.41 (m, 3H), 7.50 (d, J= 0.8 Hz, 1H), 8.17-8.20 (m, 1H).
YP-9 3.92 (s, 3H, OCH3), 5.58 (s, 2H, isoxazole-CH2), 6.80 (s, 1H), 7.08 (s, 1H, isoxazole), 7.50 (s, 1H), 7.68 (d, J= 8.0 Hz, 2H), 7.72 (d, J= 8.0 Hz, 2H).
YP-10 3.92 (s, 3H, OCH3), 5.58 (s, 2H, isoxazole-CH2), 6.80 (s, 1H), 7.08 (s, 1H, isoxazole), 7.34 (dd, 7=1.8, 1.6 Hz, 1H), 7.51-7.53 (m, 1H), 7.55 (s, 1H), 7.61 (d, 7=1.8 Hz, 1H), 7.68 (d, 7=1.6 Hz, 1H).
YP-11 3.92 (s, 3H, OCH3), 5.58 (s, 2H, isoxazole-CH2), 6.80 (s, 1H), 7.08 (s, 1H, isoxazole), 7.30 (d, J= 8.0 Hz, 2H), 7.55 (s, 1H), 7.72 (d, J= 8.0 Hz, 2H).
YP-12 3.92 (s, 3H, OCH3), 5.58 (s, 2H, isoxazole-CH2), 6.80 (s, 1H), 7.08 (s, 1H, isoxazole), 7.28 (dd, 7=1.2, 1.4 Hz, 1H), 7.49 (d, 7=1.5 Hz, 1H), 7.55 (s, 1H), 7.71-7.73 (m, 1H), 7.76-7.77 (m, 1H).
YP-13 3.92 (s, 3H, OCH3), 5.59 (s, 2H, isoxazole-CH2), 7.29 (d, 7=0.8 Hz, 1H), 7.31 (s, 1H, isoxazole), 7.49 (d, 7=1.2 Hz, 1H), 7.61 (d, 7=8.4 Hz, 2H), 7.94 (d, 7=8.8 Hz, 2H).
YP-14 3.92 (s, 3H, OCH3), 5.62 (s, 2H, isoxazole-CH2), 7.16 (s, 1H, isoxazole), 7.28 (d, 7= 0.8 Hz, 1H), 7.48-7.52 (m, 2H), 7.54-7.58 (m, 1H), 7.67 (dd,7= 1.2, 1.2 Hz, 1H), 7.72 (dd, 7= 1.6, 1.6 Hz, 1H)
YP-15 3.93 (s, 3H, OCH3), 5.59 (s, 2H, isoxazole-CH2), 7.30 (d, J= 7.2 Hz, 2H), 7.49 (s, 1H, isoxazole), 7.75 (d, J= 8.8 Hz, 2H), 7.85 (s, 1H), 7.87 (s, 1H).
Page 19
2020100093 17 Jan 2020
YP-16 3.92 (s, 3H, OCH3), 5.59 (s, 2H, isoxazole-CH2), 7.29 (d, 7=0.8 Hz, 1H), 7.31 (s, 1H, isoxazole), 7.49 (d, 7=1.2 Hz, 1H), 7.61 (d, 7=8.4 Hz, 2H), 7.94 (d, 7=8.8 Hz, 2H).
YP-17 3.92 (s, 3H, OCH3), 5.62 (s, 2H, isoxazole-CH2), 7.16 (s, 1H, isoxazole), 7.28 (d,7= 0.8 Hz, 1H), 7.48-7.52 (m, 2H), 7.54-7.58 (m, 1H), 7.67 (dd,7= 1.2, 1.2 Hz, 1H), 7.72 (dd,7= 1.6, 1.6 Hz, 1H).
YP-18 3.92 (s, 3H, OCH3), 5.62 (s, 2H, isoxazole-CH2), 7.16 (s, 1H, isoxazole), 7.28 (d, J= 0.8 Hz, 1H), 7.40-7.44 (m, 1H), 7.46 (s, 1H), 7.55 (s, 1H), 7.57 (d, J= 2.2 Hz, 1H), 7.73 (d, 7=2.3 Hz, 1H).
YP-19 3.92 (s, 3H, OCH3), 5.62 (s, 2H, isoxazole-CH2), 7.16 (s, 1H, isoxazole), 7.28 (d, J= 0.8 Hz, 1H), 7.55 (s, 1H), 8.05 (d, 7=8.4 Hz, 2H), 8.32 (d, 7=8.8 Hz, 2H).
YP-20 2.57 (s, 3H, CH3), 5.60 (s, 2H, isoxazole-CH2), 7.29 (s, 1H, isoxazole), 7.52- 7.54 (m, 3H), 7.75 (s, 1H), 7.80 (s, 1H), 7.89-7.91 (m, 2H).
YP-21 2.37 (s, 3H, CH3), 2.56 (s, 3H, CH3), 5.58 (s, 2H, isoxazole-CH2), 7.23 (s, 1H, isoxazole), 7.34 (d, 7=8.0 Hz, 2H), 7.74 (s, 1H), 7.77 (s, 1H), 7.79 (d, 7=2.0 Hz, 2H).
YP-22 1.25 (t, 7=2.6 Hz, 3H, CH3), 2.56 (s, 3H, CH3), 2.60 (q, 7=4.8 Hz, 2H, CH2CH3), 5.58 (s, 2H, isoxazole-CH2), 7.23 (s, 1H, isoxazole), 7.35 (d, 7=8.0 Hz, 2H), 7.46 (s, 1H), 7.74 (d, 7=8.0 Hz, 2H), 8.14 (s, 1H).
YP-23 1.35 (s, 9H, 3CH3), 2.56 (s, 3H, CH3), 5.58 (s, 2H, isoxazole-CH2), 7.23 (s, 1H, isoxazole), 7.38 (d, 7=8.0 Hz, 2H), 7.46 (s, 1H), 7.74 (d, 7=8.0 Hz, 2H), 8.14 (s, 1H).
YP-24 2.34 (s, 3H, CH3), 2.55(s, 3H, CH3), 2.59 (s, 6H, 2CH3), 5.58 (s, 2H, isoxazole-CH2), 7.23 (s, 1H, isoxazole), 6.97 (s, 2H), 7.46 (s, 1H), 8.14 (s, 1H).
YP-25 2.56 (s, 3H, CH3), 3.82 (s, 3H, OCH3), 5.58 (s, 2H, isoxazole-CH2), 7.08 (d, J= 8.8 Hz, 2H), 7.21 (s, 1H, isoxazole), 7.73 (s, 1H), 7.78 (s, 1H), 7.84 (d, J= 8.8 Hz, 2H).
YP-26 2.56 (s, 3H, CH3), 3.82 (s, 3H, OCH3), 5.58 (s, 2H, isoxazole-CH2), 7.05-7.07 (m, 2H), 7.21 (s, 1H, isoxazole), 7.30-7.32 (m, 1H), 7.46 (s, 1H), 8.14 (s, 1H), 8.32 (d, 7=2.4 Hz, 1H).
YP-27 2.56 (s, 3H, CH3), 3.82 (s, 3H, OCH3), 5.58 (s, 2H, isoxazole-CH2), 7.05 (d,
Page 20
2020100093 17 Jan 2020
7=1.8 Hz, H), 7.21 (s, 1H, isoxazole), 7.35-7.40 (m, 3H), 7.46 (s, 1H), 8.14 (s, 1H).
YP-28 2.56 (s, 3H, CH3), 5.58 (s, 2H, isoxazole-CTz), 7.21 (s, 1H, isoxazole), 7.46 (s, 1H), 7.68 (d, 7=8.0 Hz, 2H), 7.74 (d, 7=8.0 Hz, 2H), 8.14 (s, 1H).
YP-29 2.56 (s, 3H, CH3), 5.58 (s, 2H, isoxazole-CTz), 7.21 (s, 1H, isoxazole), 7.34 (dd, 7=1.8, 2.2 Hz, 1H), 7.46 (s, 1H), 7.51-7.53 (m, 1H), 7.61 (d, 7=2.4 Hz, 1H), 7.68 (d, 7=2.4 Hz, 1H), 8.14 (s, 1H).
YP-30 2.56 (s, 3H, CH3), 5.60 (s, 2H, isoxazole-CH2), 7.31 (s, 1H, isoxazole), 7.59- 7.61 (m, 2H), 7.73 (s, 1H), 7.79 (s, 1H), 7.92-7.94 (m, 2H).
YP-31 2.56 (s, 3H, CH3), 5.63 (s, 2H, isoxazole-CH2), 7.16 (s,lH, isoxazole), 7.48- 7.58 (m, 2H), 7.67 (d, 7=8.0 Hz, 1H), 7.73 (m, 2H), 7.79 (s, 1H).
YP-32 2.56 (s, 3H, CH3), 5.60 (s, 2H, isoxazole-CH2), 7.31 (s, 1H, isoxazole), 7.59- 7.61 (m, 2H), 7.73 (s, 1H), 7.79 (s, 1H), 7.92-7.94 (m, 2H).
YP-33 2.56 (s, 3H, CH3), 5.63 (s, 2H, isoxazole-CH2), 7.16 (s, 1H, isoxazole), 7.48- 7.58 (m, 2H), 7.67 (d, 7=8.0 Hz, 1H), 7.73 (m, 2H), 7.79 (s, 1H).
YP-34 2.56 (s, 3H, CH3), 5.63 (s, 2H, isoxazole-CTz), 7.16 (s, 1H, isoxazole), 7.43 (d, 7=2.6 Hz, 1H), 7.46 (s, 1H), 7.50 (s, 1H), 8.03 (d, 7=2.2 Hz, 1H), 8.14 (s, 1H).
YP-35 2.51 (s, 3H, CH3), 5.60 (s, 2H, isoxazole-CTz), 7.31 (s, 1H, isoxazole), 7.73 (d, J= 6.8 Hz, 2H), 7.75 (s, 1H), 7.79 (s, 1H), 7.87 (d, J= 8.8 Hz, 2H).
YP-36 2.56 (s, 3H, CH3), 5.63 (s, 2H, isoxazole-CH2), 7.16 (s, 1H, isoxazole), 7.48- 7.58 (m, 2H), 7.67 (d, 7=8.0 Hz, 1H), 7.73 (m, 2H), 7.79 (s, 1H).
YP-37 2.56 (s, 3H, CH3), 5.63 (s, 2H, isoxazole-CTz), 7.16 (s, 1H, isoxazole), 7.40 (dd, 7=2.4, 2.4 Hz, 1H), 7.46 (s, 1H), 7.47 (s, 1H), 7.56 (d, J= 2.4 Hz, 1H), 7.73 (d, 7=2.4 Hz, 1H), 8.01 (s, 1H).
YP-38 2.56 (s, 3H, CH3), 5.63 (s, 2H, isoxazole-CTz), 7.16 (s, 1H, isoxazole), 7.46 (s, 1H), 8.05 (d, 7= 6.8 Hz, 2H), 8.15 (s, 1H), 8.32 (d, 7=7.8 Hz, 2H).
YP-39 3.92 (s, 3H, OCH3), 5.59 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.28 (s, 1H, isoxazole), 7.30 (s, 1H), 7.50-7.53 (m, 4H), 7.89-7.91 (m, 2H).
YP-40 2.37 (s, 3H, CH3), 3.92 (s, 3H, OCH3), 5.58 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CQ), 7.24 (s, 1H, isoxazole), 7.29 (d, 7= 1.2 Hz, 1H), 7.34
Page 21
2020100093 17 Jan 2020
(d, J= 8.0 Hz, 2H), 7.50 (d, J= 1.2 Hz, 1H), 7.80 (d, J= 8.0 Hz, 2H).
YP-41 1.29 (t, 3H, CH3, J= 7.6 Hz), 2.72 (q, 2H, CH2, J= 7.6 Hz), 3.92 (s, 3H, OCH3), 5.58 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CO), 7.24 (s, 1H, isoxazole), 7.29 (d, J= 1.2 Hz, 1H), 7.34 (d, J= 8.0 Hz, 2H), 7.50 (d, J = 1.2 Hz, 1H), 7.80 (d, J= 8.0 Hz, 2H)
YP-42 1.35 (s, 9H, 3CH3), 3.92 (s, 3H, OCH3), 5.58 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CQ), 7.24 (s, 1H, isoxazole), 7.29 (d, 7= 1.2 Hz, 1H), 7.34 (d, 7= 8.0 Hz, 2H), 7.50 (d, 7= 1.2 Hz, 1H), 7.80 (d, 7= 8.0 Hz, 2H)
YP-43 2.15 (s, 6H, 2CH3), 2.31 (s, 3H, CH3), 3.92 (s, 3H, OCH3), 5.58 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CQ), 7.24 (s, 1H, isoxazole), 7.29 (d,7= 1.2 Hz, 1H), 7.34 (d,7=8.0 Hz, 2H), 7.50 (d, 7= 1.2 Hz, 1H), 7.80 (d, 7= 8.0 Hz, 2H)
YP-44 3.82 (s, 3H, OCH3), 3.92 (s, 3H, OCH3), 5.56 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CO), 7.08 (d, 7= 8.8 Hz, 2H), 7.21(s, 1H, isoxazole), 7.29 (d,7= 1.2 Hz, 1H), 7.50 (d, 7= 0.8 Hz, 1H), 7.84 (d, 7= 8.8 Hz, 2H)
YP-45 3.82 (s, 3H, OCH3), 3.92 (s, 3H, OCH3), 5.56 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CO), 7.01-7.08 (m, 2H), 7.42-7.46 (m, 1H), 7.21 (s, 1H, isoxazole), 7.29 (d, J= 1.2 Hz, 1H), 7.50 (d, J= 0.8 Hz, 1H), 8.17-8.20 (m, 1H).
YP-46 3.82 (s, 3H, OCH3), 3.92 (s, 3H, OCH3), 5.56 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CO), 7.21 (s, 1H, isoxazole), 7.29 (d, J= 1.2 Hz, 1H), 7.38-7.41 (m, 3H), 7.50 (d, 7= 0.8 Hz, 1H), 8.17-8.20 (m, 1H).
YP-47 3.92 (s, 3H, OCH3), 5.58 (s, 2H, isoxazole-CH2), 6.80 (s, 1H), 6.44 (t, 7=4.6 Hz, 1H, NH-CO), 7.08 (s, 1H, isoxazole), 7.50 (s, 1H), 7.68 (d, 7= 8.0 Hz, 2H), 7.72 (d, 7=8.0 Hz, 2H).
YP-48 3.92 (s, 3H, OCH3), 5.58 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 6.80 (s, 1H), 7.08 (s, 1H, isoxazole), 7.34 (dd, 7=1.8, 1.6 Hz, 1H), 7.517.53(m, 1H), 7.55 (s, 1H), 7.61 (d, 7=1.8 Hz, 1H), 7.68 (d, 7=1.6 Hz, 1H).
YP-49 3.92 (s, 3H, OCH3), 5.58 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 6.80 (s, 1H), 7.08 (s, 1H, isoxazole), 7.30 (d, 7= 8.0 Hz, 2H), 7.55 (s, 1H), 7.72 (d, 7=8.0 Hz, 2H).
YP-50 3.92 (s, 3H, OCH3), 5.58 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 6.80 (s, 1H), 7.08 (s, 1H, isoxazole), 7.28 (dd, 7=1.2, 1.4 Hz, 1H), 7.49
Page 22
2020100093 17 Jan 2020
(d, 7=1.5 Hz, 1H), 7.55 (s, 1H), Ί.ΊΧ-Ί.Ί3 (m, 1H), 7.76-7.77 (m, 1H).
YP-51 3.92 (s, 3H, OCH3), 5.59 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.29 (d, 7=0.8 Hz, 1H), 7.3l(s, 1H, isoxazole), 7.49 (d, 7=1.2 Hz, 1H), 7.61 (d, 7=8.4 Hz, 2H), 7.94 (d, 7=8.8 Hz, 2H)
YP-52 3.92 (s, 3H, OCH3), 5.62 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.16 (s, 1H, isoxazole), 7.28 (d, J= 0.8Hz, 1H), 7.48-7.52 (m, 2H), 7.54- 7.58 (m, 1H), 7.67 (dd,7= 1.2, 1.2 Hz, 1H), 7.72 (dd,7= 1.6, 1.6 Hz, 1H)
YP-53 3.93(s, 3H, OCH3), 5.59 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.30 (d, J= 7.2 Hz, 2H), 7.49(s, 1H, isoxazole), 7.75 (d, J= 8.8 Hz, 2H), 7.85 (s, 1H), 7.87 (s, 1H).
YP-54 3.92 (s, 3H, OCH3), 5.59 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.29 (d, 7=0.8 Hz, 1H), 7.31 (s, 1H, isoxazole), 7.49 (d, 7=1.2 Hz, 1H), 7.61 (d, 7=8.4 Hz, 2H), 7.94 (d, 7=8.8 Hz, 2H).
YP-55 3.92 (s, 3H, OCH3), 5.62 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.16 (s, 1H, isoxazole), 7.28 (d, J= 0.8 Hz, 1H), 7.48-7.52 (m, 2H), 7.54-7.58 (m, 1H), 7.67 (dd,7= 1.2, 1.2 Hz, 1H), 7.72 (dd,7= 1.6, 1.6 Hz, 1H).
YP-56 3.92 (s, 3H, OCH3), 5.62 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.16 (s, 1H, isoxazole), 7.28 (d, J= 0.8 Hz, 1H), 7.40-7.44 (m, 1H), 7.46 (s, 1H), 7.55 (s, 1H), 7.57 (d, J= 2.2 Hz, 1H), 7.73 (d, 7=2.3 Hz, 1H).
YP-57 3.92 (s, 3H, OCH3), 5.62 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.16 (s, 1H, isoxazole), 7.28 (d, J= 0.8 Hz, 1H), 7.55 (s, 1H), 8.05 (d, 7=8.4 Hz, 2H), 8.32 (d, 7=8.8 Hz, 2H).
YP-58 2.57 (s, 3H, CH3), 5.60 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.29 (s, 1H, isoxazole), 7.52-7.54 (m, 3H), 7.75 (s, 1H), 7.80 (s, 1H), 7.89-7.91 (m, 2H).
YP-59 2.37 (s, 3H, CH3), 2.56 (s, 3H, CH3), 5.58 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CO), 7.23 (s, 1H, isoxazole), 7.34 (d, 7=8.0 Hz, 2H), 7.74 (s, 1H), 7.77 (s, 1H), 7.79 (d, 7=2.0 Hz ,2H).
YP-60 1.25 (t, 7=2.6 Hz, 3H, CH3), 2.56 (s, 3H, CH3), 2.60 (q, 7=4.8 Hz, 2H, CH2CH3), 5.58 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CO), 7.23 (s, 1H, isoxazole), 7.35 (d, 7=8.0 Hz, 2H), 7.46 (s, 1H), 7.74 (d, 7=8.0 Hz, 2H), 8.14 (s, 1H).
Page 23
2020100093 17 Jan 2020
YP-61 1.35 (s, 9H, 3CH3), 2.56 (s, 3H, CH3), 5.58 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CO), 7.23 (s, 1H, isoxazole), 7.38 (d, 7=8.0 Hz, 2H), 7.46 (s, 1H), 7.74 (d, 7=8.0 Hz, 2H), 8.14 (s, 1H).
YP-62 2.34 (s, 3H, CH3), 2.55 (s, 3H, CH3), 2.59 (s, 6H, 2CH3), 5.58 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CO), 7.23 (s, 1H, isoxazole), 6.97 (s, 2H), 7.46 (s, 1H), 8.14 (s, 1H).
YP-63 2.56 (s, 3H, CH3), 3.82 (s, 3H, OCH3), 5.58 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CO), 7.08 (d, J= 8.8 Hz, 2H), 7.21 (s, 1H, isoxazole), 7.73 (s, 1H), 7.78 (s, 1H), 7.84 (d, J= 8.8 Hz, 2H).
YP-64 2.56 (s, 3H, CH3), 3.82 (s, 3H, OCH3), 5.58 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CO), 7.05-7.07 (m, 2H), 7.21 (s, 1H, isoxazole), 7.30-7.32 (m, 1H), 7.46 (s, 1H), 8.14 (s, 1H), 8.32 (d,7= 2.4 Hz, 1H).
YP-65 2.56 (s, 3H, CH3), 3.82 (s, 3H, OCH3), 5.58 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CO), 7.05 (d, 7=1.8 Hz, H), 7.21 (s, 1H, isoxazole), 7.35- 7.40 (m, 3H), 7.46 (s, 1H), 8.14 (s, 1H).
YP-66 2.56 (s, 3H, CH3), 5.58 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.21 (s, 1H, isoxazole), 7.46 (s, 1H), 7.68 (d, 7=8.0 Hz, 2H), 7.74 (d, 7=8.0 Hz, 2H), 8.14 (s, 1H).
YP-67 2.56 (s, 3H, CH3), 5.58 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.21 (s, 1H, isoxazole), 7.34 (dd, 7=1.8, 2.2 Hz, 1H), 7.46 (s, 1H), 7.51- 7.53 (m, 1H), 7.61 (d, 7=2.4 Hz, 1H), 7.68 (d, 7=2.4 Hz, 1H), 8.14 (s, 1H).
YP-68 2.56 (s, 3H, CH3), 5.60 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.31 (s, 1H, isoxazole), 7.59-7.61 (m, 2H), 7.73 (s, 1H), 7.79 (s, 1H), 7.92-7.94 (m, 2H).
YP-69 2.56 (s, 3H, CH3), 5.63 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.16 (s, 1H, isoxazole), 7.48-7.58 (m, 2H), 7.67 (d, 7=8.0 Hz, 1H), 7.73 (m, 2H), 7.79 (s, 1H).
YP-70 2.56 (s, 3H, CH3), 5.60 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.31 (s, 1H, isoxazole), 7.59-7.61 (m, 2H), 7.73 (s, 1H), 7.79 (s, 1H), 7.92-7.94 (m, 2H).
YP-71 2.56 (s, 3H, CH3), 5.63 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.16 (s, 1H, isoxazole), 7.48-7.58 (m, 2H), 7.67 (d, 7=8.0 Hz, 1H), 7.73 (m, 2H), 7.79 (s, 1H).
Page 24
2020100093 17 Jan 2020
YP-72 2.56 (s, 3H, CH3), 5.63 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.16 (s, 1H, isoxazole), 7.43 (d, 7=2.6 Hz, 1H), 7.46 (s, 1H), 7.50 (s, 1H), 8.03 (d, 7=2.2 Hz, 1H), 8.14 (s, 1H).
YP-73 2.51 (s, 3H, CH3), 5.60 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.31 (s, 1H, isoxazole), 7.73 (d, J= 6.8 Hz, 2H), 7.75 (s, 1H), 7.79 (s, 1H), 7.87 (d, 7= 8.8 Hz, 2H).
YP-74 2.56 (s, 3H, CH3), 5.63 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.16 (s, 1H, isoxazole), 7.48-7.58 (m, 2H), 7.67 (d, 7=8.0 Hz, 1H), 7.73 (m, 2H), 7.79 (s, 1H).
YP-75 2.56 (s, 3H, CH3), 5.63 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.16 (s, 1H, isoxazole), 7.40 (dd, 7=2.4, 2.4 Hz, 1H), 7.46 (s, 1H), 7.47 (s, 1H), 7.56 (d, J= 2.4 Hz, 1H), 7.73 (d, 7=2.4 Hz, 1H), 8.01 (s, 1H).
YP-76 2.56 (s, 3H, CH3), 5.63 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.16 (s, 1H, isoxazole), 7.46 (s, 1H), 8.05 (d, J= 6.8 Hz, 2H), 8.15 (s, 1H), 8.32 (d, 7=7.8 Hz, 2H).
YP-77 5.63 (s, 2H, isoxazole-CH2), 7.16 (s, 1H, isoxazole), 7.41-7.51 (m, 3H), 7.79- 7.82 (m, 2H), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-78 2.34 (s, 3H, CH3), 5.63 (s, 2H, isoxazole-CH2), 7.16 (s, 1H, isoxazole), 7.29 (d, 7=8.0 Hz, 2H), 7.70 (d, 7=8.0 Hz, 2H), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-79 1.28 (t, 7=2.3 Hz, 3H, CH3), 2.65 (q, 7=2.4 Hz, 2H, CH2CH3), 5.63 (s, 2H, isoxazole-CH2), 7.16 (s, 1H, isoxazole), 7.29 (d, 7=8.0 Hz, 2H), 7.70 (d, 7=8.0 Hz, 2H), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-80 1.36 (s, 9H, 3CH3), 5.63 (s, 2H, isoxazole-CH2), 7.16 (s, 1H, isoxazole), 7.29 (d, 7=8.0 Hz, 2H), 7.70 (d, 7=8.0 Hz, 2H), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-81 2.23 (s, 3H, CH3), 2.62 (s, 6H, 2CH3), 5.63 (s, 2H, isoxazole-CH2), 7.06(s, 2H), 7.16 (s, 1H, isoxazole), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-82 3.85 (s, 3H, OCH3), 5.63 (s, 2H, isoxazole-CH2), 7.06 (d, 7=7.2 Hz, 2H), 7.16 (s, 1H, isoxazole), 7.55 (d, 7=8.0 Hz, 2H), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-83 3.85 (s, 3H, OCH3), 5.63 (s, 2H, isoxazole-CH2), 7.05-7.07 (m, 2H), 7.16 (s, 1H, isoxazole), 7.30-7.32 (m, 1H), 7.92 (d, J= 7.8 Hz, 2H), 8.32 (d, 7=2.4 Hz,
Page 25
2020100093 17 Jan 2020
1H), 8.90 (d, 7=8.2 Hz, 2H).
YP-84 3.85 (s, 3H, OCH3), 5.63 (s, 2H, isoxazole-CH2), 7.05 (d, 7=2.0 Hz, 1H), 7.16 (s, 1H, isoxazole), 7.35-7.40 (m, 3H), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-85 5.63 (s, 2H, isoxazole-CH2), 7.16 (s, 1H, isoxazole), 7.68 (d, 7=8.0 Hz, 2H), 7.74 (d, 7=8.0 Hz, 2H), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-86 5.63 (s, 2H, isoxazole-CH2), 7.16 (s, 1H, isoxazole), 7.34 (dd, 7=2.2, 1.8 Hz, 1H), 7.51 (dd, 7=2.2, 1.8 Hz, 1H), 7.61 (dd, 7=2.2, 2.8 Hz, 1H), 7.68 (dd, 7=2.2, 1.8 Hz, 1H), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-87 5.63 (s, 2H, isoxazole-CH2), 7.16 (s, 1H, isoxazole), 7.30 (d, 7=8.0 Hz, 2H), 7.92 (d, 7=8.0 Hz, 2H), 7.95 (d, J= 7.8 Hz, 2H), 8.91 (d, 7=8.2 Hz, 2H).
YP-88 5.63 (s, 2H, isoxazole-CH2), 7.16 (s, 1H, isoxazole), 7.28 (dd, 7=2.0, 2.2 Hz, 1H), 7.49 (d, 7=2.4 Hz, 1H), 7.71-7.75 (m, 1H), 7.77 (d, 7=2.4 Hz, 1H), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-89 5.63 (s, 2H, isoxazole-CH2), 7.16 (s, 1H, isoxazole), 7.30 (d, 7=8.0 Hz, 2H), 7.92 (d, 7=8.0 Hz, 2H), 7.95 (d, J= 7.8 Hz, 2H), 8.91 (d, 7=8.2 Hz, 2H).
YP-90 5.63 (s, 2H, isoxazole-CH2), 7.16 (s, 1H, isoxazole), 7.28 (dd, 7=2.0, 2.2 Hz, 1H), 7.49 (d, 7=2.4 Hz, 1H), 7.71-7.75 (m, 1H), 7.77 (d, 7=2.4 Hz, 1H), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-91 5.63 (s, 2H, isoxazole-CH2), 7.16 (s, 1H, isoxazole), 7.45 (d, 7= 2.4 Hz, 1H), 7.50 (s, 1H), 7.92 (d, J= 7.8 Hz, 2H), 8.06 (d, 7=2.4 Hz, 1H), 8.90 (d, 7=8.2 Hz, 2H).
YP-92 5.63 (s, 2H, isoxazole-CH2), 7.16 (s, 1H, isoxazole), 7.30 (d, 7=8.0 Hz, 2H), 7.92 (d, 7=8.0 Hz, 2H), 7.95 (d, J= 7.8 Hz, 2H), 8.91 (d, 7=8.2 Hz, 2H).
YP-93 5.63 (s, 2H, isoxazole-CH2), 7.16 (s, 1H, isoxazole), 7.28 (dd, 7=2.0, 2.2 Hz, 1H), 7.49 (d, 7=2.4 Hz, 1H), 7.71-7.75 (m, 1H), 7.77 (d, 7=2.4 Hz, 1H), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-94 5.63 (s, 2H, isoxazole-CH2), 7.16 (s, 1H, isoxazole), 7.40-7.44(m, 1H), 7.46 (s, 1H), 7.56 (d, 7=2.4 Hz, 1H), 7.73 (d, 7=2.4 Hz, 1H), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-95 5.63 (s, 2H, isoxazole-CH2), 7.16 (s, 1H, isoxazole), 7.92 (d, 7= 7.8 Hz, 2H), 8.05 (d, J= 7.6 Hz, 2H), 8.38 (d, J= 7.8 Hz, 2H), 9.12 (d, J= 7.8 Hz, 2H),
YP-97 2.34 (s, 3H, CH3), 5.63 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-
Page 26
2020100093 17 Jan 2020
CO), 7.16 (s, 1H, isoxazole), 7.29 (d, 7=8.0 Hz, 2H), 7.70 (d, 7=8.0 Hz, 2H), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-98 1.28 (t, 7=2.3 Hz, 3H, CH3), 2.65 (q, 7=2.4 Hz, 2H, CH2CH3), 5.63 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CO), 7.16 (s, 1H, isoxazole), 7.29 (d, 7=8.0 Hz, 2H), 7.70 (d, 7=8.0 Hz, 2H), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-99 1.36 (s, 9H, 3CH3), 5.63 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.16 (s, 1H, isoxazole), 7.29 (d, 7=8.0 Hz, 2H), 7.70 (d, 7=8.0 Hz, 2H), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-100 2.23 (s, 3H, CH3), 2.62 (s, 6H, 2CH3), 5.63 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CO), 7.06 (s, 2H), 7.16 (s, 1H, isoxazole), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-101 3.85 (s, 3H, OCH3), 5.63 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.06 (d, 7=7.2 Hz, 2H), 7.16 (s, 1H, isoxazole), 7.55 (d, 7=8.0 Hz, 2H), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-102 3.85 (s, 3H, OCH3), 5.63 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.05-7.07 (m, 2H), 7.16 (s, 1H, isoxazole), 7.30-7.32 (m, 1H), 7.92 (d, J= 7.8 Hz, 2H), 8.32 (d, 7=2.4 Hz, 1H), 8.90 (d, 7=8.2 Hz, 2H).
YP-103 3.85 (s, 3H, OCH3), 5.63 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NHCO), 7.05 (d, 7=2.0 Hz, 1H), 7.16 (s, 1H, isoxazole), 7.35-7.40 (m, 3H), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-104 5.63 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CO), 7.16 (s, 1H, isoxazole), 7.68 (d, 7=8.0 Hz, 2H), 7.74 (d, 7=8.0 Hz, 2H), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-105 5.63 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CO), 7.16 (s, 1H, isoxazole), 7.34 (dd, 7=2.2, 1.8 Hz, 1H), 7.51 (dd, 7=2.2, 1.8 Hz, 1H), 7.61 (dd, 7=2.2, 2.8 Hz, 1H), 7.68 (dd, 7=2.2, 1.8 Hz, 1H), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-106 5.63 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CO), 7.16 (s, 1H, isoxazole), 7.30 (d, 7=8.0 Hz, 2H), 7.92 (d, 7=8.0 Hz, 2H), 7.95 (d, J= 7.8 Hz, 2H), 8.91 (d, 7=8.2 Hz, 2H).
YP-107 5.63 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CO), 7.16 (s, 1H, isoxazole), 7.28 (dd, 7=2.0, 2.2 Hz, 1H), 7.49 (d, 7=2.4 Hz, 1H), 7.71-7.75
Page 27
2020100093 17 Jan 2020
(m, 1H), 7.77 (d, 7=2.4 Hz, 1H), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-108 5.63 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CQ), 7.16 (s, 1H, isoxazole), 7.30 (d, 7=8.0 Hz, 2H), 7.92 (d, 7=8.0 Hz, 2H), 7.95 (d, J= 7.8 Hz, 2H), 8.91 (d, 7=8.2 Hz, 2H).
YP-109 5.63 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CQ), 7.16 (s, 1H, isoxazole), 7.28 (dd, 7=2.0, 2.2 Hz, 1H), 7.49 (d, 7=2.4 Hz, 1H), 7.71-7.75 (m, 1H), 7.77 (d, 7=2.4 Hz, 1H), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-110 5.63 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CQ), 7.16 (s, 1H, isoxazole), 7.45 (d, J= 2.4 Hz, 1H), 7.50 (s, 1H), 7.92 (d, J= 7.8 Hz, 2H), 8.06(d, 7=2.4 Hz, 1H), 8.90 (d, 7=8.2 Hz, 2H).
YP-111 5.63 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CQ), 7.16 (s, 1H, isoxazole), 7.30 (d, 7=8.0 Hz, 2H), 7.92 (d, 7=8.0 Hz, 2H), 7.95 (d, J= 7.8 Hz, 2H), 8.91 (d, 7=8.2 Hz, 2H).
YP-112 5.63 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CQ), 7.16 (s, 1H, isoxazole), 7.28 (dd, 7=2.0, 2.2 Hz, 1H), 7.49 (d, 7=2.4 Hz, 1H), 7.71-7.75 (m, 1H), 7.77 (d, 7=2.4 Hz, 1H), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-113 5.63 (s, 2H, isoxazole-CH2), 6.44 (t, 7=4.6 Hz, 1H, NH-CQ), 7.16 (s, 1H, isoxazole), 7.40-7.44 (m, 1H), 7.46 (s, 1H), 7.56 (d, 7=2.4 Hz, 1H), 7.73 (d, 7=2.4 Hz, 1H), 7.92 (d, J= 7.8 Hz, 2H), 8.90 (d, 7=8.2 Hz, 2H).
YP-114 5.63 (s, 2H, isoxazole-CH2), 6.65 (t, 7=4.6 Hz, 1H, NH-CQ), 7.16 (s, 1H, isoxazole), 7.92 (d, J= 7.8 Hz, 2H), 8.05 (d, J= 7.6 Hz, 2H), 8.38 (d, J= 7.8 Hz, 2H), 9.12 (d, J= 7.8 Hz, 2H),
Example 3 Biological activity test
The MTT method was used to test the activity against the colorectal cancer cell line HCT-116, human lung cancer cell line A549 and breast cancer cell line MCF-7 using the above specific compounds. The specific test process is as follows:
(1) The lung cancer cell line A549 was laid in a 96-well plate, added with 100 pL medium to culture until the cells grow to 90%. 1 pL drug was added to the wells. Each drug was tested at 8 different concentrations (respectively are the initial concentrations of drugs, 50
Page 28
2020100093 17 Jan 2020 μΜ, 5 μΜ, 500 ηΜ, 50 ηΜ, 5 ηΜ, 500 ρΜ, 50 ρΜ). Three wells of replicates of each drug concentration were made in parallel, and after 18 hours of incubation, each well was added with prepared 20 pL of 5 mg / mL MTT solution. After 4 hours, the medium was aspirated and 150 pL DMSO was added to each well. The optical density (OD) of the test compounds were measured at a wavelength of 595 nm. The negative control was DMSO. The inhibition rate was calculated according to the formula.
Negative control OD - Drug OD
Inhibition rate(%)= X 100
Negative control OD
The IC50 value was calculated by GraphPad Prism 5 software.
(2) The screening process of colorectal cancer cell line HCT-116 and breast cancer cell line MCF-7 was the same as that of lung cancer cell line A549.
The test results of the preferred compounds for inhibiting the activity of human lung cancer cells A549, colorectal cancer cell line HCT-116 and breast cancer cell line MCF-7 are shown in Tables 3, 4 and 5 below.
Table 3-Test results of the compounds of formula (I) for inhibiting the activity of human lung cancer cell A549
Compound No. IC50 (μΜ) Compound No. IC50 (μΜ)
YP-1 4.73 YP-13 219.3
YP-6 694.9 YP-28 27.6
Gefitinib 21.55
Table 4-Test results of the compounds of formula (I) for inhibiting the activity of colorectal cancer cell line HCT-116
Compound No. ICso(pM) Compound No. ICso(pM)
YP-1 3.60 YP-13 550.2
YP-6 295.0 YP-28 273.3
Gefitinib 17.9
Table 5- Test results of the compounds of formula (I) for inhibiting the activity of breast cancer cell line MCF-7
Page 29
2020100093 17 Jan 2020
Compound No. IC50(pM) Compound No. IC50(pM)
YP-1 170.8 YP-13 197.3
YP-6 114.7 YP-28 106.8
Gefitinib 20.68
The embodiments of the present disclosure have been described above. However, this disclosure is not limited to the said embodiment. Any modification, equivalent replacement, or improvement made within the spirit and principle of embodiments of the present disclosure shall be included in the protection scope of embodiments of the present disclosure.

Claims (5)

1. An isonicotinic acid derivative represented by formula (I), a stereoisomer, a racemate, a tautomer, or a pharmaceutically acceptable salt thereof,
Figure AU2020100093A4_C0001
(I) wherein,
Z is selected from the group consisting of O, S, and NR3, wherein R3 is hydrogen or Ci~C6~ alkyl;
Ri is selected from the group consisting of C j-Ce alkyl, C j-Ce alkoxy, halogenated C j-Ce alkyl, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclyloxy and halogen;
R2 is selected from the group consisting of halogen, cyano, nitro, C j-Ce alkyl, C j-Ce alkoxy, and halogenated C j-Ce alkyl;
m is an integer from 0 to 4;
n is an integer from 0 to 5;
provided that when Z is NR3, m is 0 and n is 1, R2 is not a halogen.
2. The isonicotinic acid derivative, stereoisomer, racemate, tautomer, or pharmaceutically acceptable salt thereof according to claim 1, wherein in formula (I):
Z is O or NH;
Ri is selected from the group consisting of fluorine, chlorine, bromine, Ci~C4 alkyl, Ci~C4 alkoxy, halogenated Ci~C4 alkyl, and phenoxy;
R2 is selected from the group consisting of fluorine, chlorine, bromine, nitro, Ci~C4 alkyl, Cj~C4 alkoxy, and halogenated Ci~C4 alkyl;
m is an integer of 0,1, 2; when m is greater than 1, Ri may be the same or different groups;
n is an integer of 0, 1, 2, 3; when n is greater than 1, R2 may be the same or different groups;
provided that when Z is NR3, m is 0 and n is 1, R2 is not fluorine, chlorine, or bromine.
3. The isonicotinic acid derivative, stereoisomer, racemate, tautomer, or pharmaceutically acceptable salt thereof according to claims 1 or 2, wherein in formula (I):
Z is O;
Ri is selected from 2- and / or 6-position substituents on 3-pyridyl, and the substituents are selected from the group consisting of fluorine, chlorine, bromine, Ci~C4 alkyl, and Ci~C4
Page 31
2020100093 17 Jan 2020 alkoxy;
R2 is selected from 2- and / or 4- and / or 6-position substituents on 1 -phenyl, and the substituents are selected from the group consisting of fluorine, chlorine, bromine, nitro, Cj~C4 alkyl, Ci~C4 alkoxy and halogenated Ci~C4 alkyl.
4. The isonicotinic acid derivative, stereoisomer, racemate, tautomer, or pharmaceutically acceptable salt thereof according to claims 1 or 2, wherein, the isonicotinic acid derivative represented by the formula (I) is selected from any one of the following compounds:
Figure AU2020100093A4_C0002
Page 32
2020100093 17 Jan 2020
Figure AU2020100093A4_C0003
Figure AU2020100093A4_C0004
Figure AU2020100093A4_C0005
Figure AU2020100093A4_C0006
Figure AU2020100093A4_C0007
Figure AU2020100093A4_C0008
Page 33
2020100093 17 Jan 2020
Figure AU2020100093A4_C0009
Page 34
2020100093 17 Jan 2020
Figure AU2020100093A4_C0010
Figure AU2020100093A4_C0011
Figure AU2020100093A4_C0012
Figure AU2020100093A4_C0013
Figure AU2020100093A4_C0014
Figure AU2020100093A4_C0015
Page 35
2020100093 17 Jan 2020
Figure AU2020100093A4_C0016
Figure AU2020100093A4_C0017
Figure AU2020100093A4_C0018
Figure AU2020100093A4_C0019
Figure AU2020100093A4_C0020
Figure AU2020100093A4_C0021
Figure AU2020100093A4_C0022
Figure AU2020100093A4_C0023
Page 36
Figure AU2020100093A4_C0024
5. A pharmaceutical composition comprising a therapeutically effective amount of at least one selected from the compounds of the stereoisomer, racemate, tautomer, and pharmaceutically acceptable salt thereof according to any one of claims 1 to 4.
AU2020100093A 2019-03-19 2020-01-17 Isonicotinic acid derivative and preparation method and application thereof technical field Active AU2020100093A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019102094862 2019-03-19
CN201910209486.2A CN109942566B (en) 2019-03-19 2019-03-19 Isonicotinic acid derivative and preparation method and application thereof

Publications (1)

Publication Number Publication Date
AU2020100093A4 true AU2020100093A4 (en) 2020-02-27

Family

ID=67010278

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020100093A Active AU2020100093A4 (en) 2019-03-19 2020-01-17 Isonicotinic acid derivative and preparation method and application thereof technical field

Country Status (2)

Country Link
CN (1) CN109942566B (en)
AU (1) AU2020100093A4 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074501A1 (en) * 2002-03-07 2003-09-12 Sds Biotech K.K. Substituted isoxazole alkylamine derivative and agri- and horticultural fungicide
JP2007537246A (en) * 2004-05-12 2007-12-20 バイオランクス カンパニー リミテッド Cancer preventive and therapeutic agent containing nicotinic acid derivative as active ingredient
CN104926792B (en) * 2015-07-08 2018-10-02 厦门稀土材料研究所 Metronidazole derivative and its preparation method and application
CN111646986B (en) * 2017-09-13 2022-03-25 厦门稀土材料研究所 Nicotinic acid derivative and preparation method and application thereof

Also Published As

Publication number Publication date
CN109942566A (en) 2019-06-28
CN109942566B (en) 2021-07-23

Similar Documents

Publication Publication Date Title
CN109776445B (en) Benzoxadiazole compound, preparation method and medical application thereof
KR20220122662A (en) Quinazoline Compounds Containing Spiro Rings
ES2906785T3 (en) 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (CHK1) inhibitors, and their preparations and applications
KR101414931B1 (en) Acylthiourea compound or salt thereof, and use of the compound or the salt
KR20210143803A (en) Novel small molecule inhibitors of TEAD transcription factors
KR101738866B1 (en) Cyclic N,N&#39;-diarylthioureas and N,N&#39;-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same
WO2014165090A1 (en) Compounds for the treatment of tuberculosis
JP2021176847A (en) Substituted five-membered and six-membered heterocyclic compound, its preparation method, combination with medicine and its usage
AU2019218187A1 (en) Dioxinoquinoline compounds, preparation method and uses thereof
US10501466B2 (en) WDR5 inhibitors and modulators
ES2927529T3 (en) condensed heterocyclic compound
KR20160018686A (en) Bicyclic nitrogen-containing aromatic heterocyclic amide compound
US10519119B2 (en) Nicotinic acid derivatives, their preparation and the use thereof
KR102526281B1 (en) Oxazino-quinazoline and oxazino-quinoline-type compounds, preparation methods and uses thereof
AU2020100093A4 (en) Isonicotinic acid derivative and preparation method and application thereof technical field
CN108473504B (en) Novel dihydropyranopyrimidinone derivatives and uses thereof
CN112225742B (en) Compound for inhibiting VEGFR activity, preparation method and application
EP4098647A1 (en) Disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition for suppressing cancer growth comprising same as active ingredient
AU2019101281A4 (en) Pyridine-2-carboxylic derivative, and preparation method and use thereof
US11407760B2 (en) Dioxinoquinoline compounds, preparation method and uses thereof
KR101723881B1 (en) Novel triazole derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating Aurora Kinase relating diseases containing the same as an active ingredient
CN111116572A (en) Oxadiazole derivatives, their preparation and use
CN111039940B (en) Aurora A kinase inhibitor, preparation method, pharmaceutical composition and application thereof
WO2023046114A1 (en) Pteridinone derivative and use thereof
CN115803325B (en) EGFR inhibitor and preparation method and application thereof

Legal Events

Date Code Title Description
FGI Letters patent sealed or granted (innovation patent)